dissertation motivation college admission essays for sale dissertation for mphil in computer science teaching for critical thinking research paper on legalizing marijuana dissertation on enterprise risk management best resume writing service for educators in uk dissertation on correlational study how to write a research analysis paper
Skip to main content

Vim3 and Mxi-2 antibodies - Non-invasive markers for diagnosis and differentiation of benign and malignant renal carcinoma


Abstract

The invention relates to Vimentin3 and Mxi-2 antibodies found for the non-invasive diagnosis of kidney tumors. These antibodies can make a clear differentiation of oncocytoma and RCC types and allow targeted therapeutic measurements.


Background

Kidney tumors are known to develop to benign (oncocytoma) and malignant (RCC) types. One diagnostic drawback about oncocytoma is their ability to mimic the morphology, histology, and imaging characteristics of RCC subtypes. In many cases, oncocytoma are even considered as RCC and vice versa unless proved otherwise.


Images & Videos


Solution

Since no specific, diagnostic and non-invasive tests exist for the differentiation of kidney tumors, it remains a challenge to set the right diagnosis and surgical intervention. The present invention provides antibodies that exclusively target the biomarkers Vimentin 3 (Vim3) and Mxi-2 from oncocytoma and RCC, respectively.


Advantages

  • specific antibodies for the non-invasive diagnosis of kidney tumors
  • clear diagnosis and differentiation of oncocytoma and RCC types allow targeted therapeutic measurements
  • antibodies are also usable for non-invasive routine medical checkup (persons aged 55 and above)

Scope of application

The antibodies can be used for the development of a diagnostic test system based on anti-Vim3 and anti-Mxi-2 wherein the detection of Vim3 would indicate the presence of oncocytoma and Mxi-2, the presence of RCC. The test system can additionally be accompanied with an ultrasonic examination if a tumour of cyst is suspected. Another option would be using the test system as part of the standard examination for preventive diagnostic purposes. Anti-Vim3 and anti-Mxi-2 are part of pending diagnostic patent applications for which a license is offered.


Service

Anti-Vim3 and anti-Mxi-2 have already been validated in studies.


PROvendis GmbH

Dipl.-Biol. Kordula Kruber
+49.208 94105-30
kk@provendis.info
www.provendis.info
Address
Schloßstr. 11-15
45468 Mülheim an der Ruhr



Development status

Demonstration model


Patent situation

  • DE pending
  • PCT pending

Keywords

urine, urine diagnostics, tumour tissue, ELISA, lateral flow test, Western blot, immunohistology, preoperative marker, postoperative marker, differential diagnosis, non-invasive, differentiation between benign and malignant, renal tumour, renal cell carcinoma, oncocytoma, kidney, Vimentin3 antibody, Mxi-2 antibody, biomarker

Offer at Providers website


Contact | Main Office

TransferAllianz e. V.
Christiane Bach-Kaienburg
(Geschäftsführerin)

c/o TransMIT GmbH
Kerkrader Straße 3
D-35394 Gießen